Articlenpj women's health2026
Impact of telehealth genetic counseling on contralateral prophylactic mastectomy rates among multi-ethnic breast cancer patients.
Article in npj women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contralateral prophylactic mastectomy (CPM) reduces contralateral breast cancer risk but improves survival only among young BRCA1/2 carriers. With expanded germline testing (GT) and increased use of oncologist-led and telehealth genetic services post-COVID, concerns remain about patients' understanding of results and the impact on surgical decisions. We conducted a retrospective cohort study of 1,054 women with unilateral breast cancer who underwent GT at Columbia University Irving Medical Center from 2013-2022. Mean age was 51.2; 40.5% were non-Hispanic White (NHW), 28.4% Hispanic, 12.1% Black, and 10.3% Asian. Overall, 28% underwent CPM. Testing shifted from 99.7% in-person to 73.9% oncologist-led and 20.1% telehealth post-COVID. In multivariable analysis, CPM was associated with younger age, advanced stage, and pathogenic/likely pathogenic variants, but not with service delivery or VUS results. A trend toward higher CPM rates was observed among Hispanic versus NHW patients (OR = 1.34, 95% CI = 0.99-1.81, p = 0.055). Despite care delivery shifts, CPM rates remained stable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.